1 For this and other technical terms commonly used in the statistics and cancer biology communities we provide a Glossary in the Supplementary Material. summarized in Figure 2 . The rationale is similar in spirit to workflows implemented by consortia 182 such as TCGA to analyze huge populations of cancer samples [56, 57] . One of the main novelties 183 of our approach, is the exploitation of groups of exclusive alterations as a proxy to detect fitness-184 equivalent trajectories of cancer progression. This strategy is only feasible by the hypothesis-testing 185 features of the recently developed CAPRI algorithm, an algorithm uniquely addressing this crucial 186 aspect of the ensemble-level progression inference problem [40] . 187 In the Results section, we study in details a specific use-case for the pipeline, processing colorectal 188 cancer data from TCGA, where it is able to re-discover much of the existing body of knowledge 189 about colorectal cancer progression. Based on the output of this pipeline, we also propose novel 190 experimentally-verifiable hypotheses. 191 2.1 Reducing inter-tumor heterogeneity by cohort subtyping 192 In general, for each of n tumors (patients) we assume relevant (epi)genetic data to be available. We 193 do not put constraints on data gathering and selection, leaving the user to decide the appropriate 194 "resolution" of the input data. For instance, one might decide whether somatic mutations should 195 be classified by type or by location, or aggregated. Or, one might decide to lift focal CNAs to 196 4 The genuine selectivity relationship sought to be inferred are subject to the vagaries of Simpson's paradox; it can change, or worst reverse, when we try to infer them from data not suitably pre-processed. This effect (due to such paradox) manifests as data are sampled from a highly heterogenous mixture of populations of cells [40] . PiCnIc uses various mechanisms to avoid these pitfalls. In this context, it should be pointed out that input bulk sequencing data suffers also from intra-tumor heterogeneity issues, which are unfortunately intrinsic to the technology.
the lower resolution of cytobands or full arms (e.g., in a kidney cancer cohort where very long understanding of such alterations and their functional effects for the cancer under study, and no 199 single all-encompassing rationale may be provided.
200
With these data at hand, we might wish to identify cancer subtypes in the heterogeneous mixture 201 of input samples. In some cases the classification can benefit from clinical biomarkers, such as 202 evidences of certain cell types [59] , but in most cases we will have to rely on multiple clustering 
211
Using pipelines such as PicNic, we expect that the resulting subtypes will be routinely in-212 vestigated, eventually leading to distinct progression models, which shall be characteristic of the 213 population-level trends of cancer initiation and progression. . 227 We anticipate that such tools will run independently on each subtype, as driver genes will likely 228 differ across them, mimicking the different molecular properties of each group of samples; also, lists 
245
In such groups, we distinguish between hard and soft forms of exclusivity, the former assuming 246 strict exclusivity among alterations, with random errors accounting for possible overlaps (i.e., the 247 majority of samples do not share alterations from such groups), the latter admitting co-occurrences 248 (i.e., some samples might have common alterations, within a group) [77] .
249
CAPRI is currently the only algorithm which incorporates this type of information, in inferring 250 a model. Each of these groups are in fact associated with a "testable hypothesis" written in the well-251 known language of propositional Boolean formulas 5 . Consider the following example: we might be 252 informed that apc and ctnnb1 mutations show a trend of soft-exclusivity in our cohort -i.e., some 253 samples harbor both mutations, but the majority just one of the two mutated genes. Since such 254 mutations lead to -catenin deregulation (the phenotype), we might wonder whether such state of 255 affairs could be responsible for progression initiation in the tumors under study. An affermative 256 response would equate, in terms of progression, the two mutations. To test this hypothesis, one may 257 spell out formula apc _ ctnnb1 to CAPRI, which means that we are suggesting to the inference 258 engine that, besides the possible evolutionary trajectories that might be inferred by looking at the 259 two mutations as independent, trajectories involving such a "composite" event, shall be considered 260 as well. It is then up to CAPRI to decide which, of all such trajectories, is significant, in a statistical 261 sense.
262
In general, formulas allow users to test general hypotheses about complex model structures 263 involving multiple genes and alterations. These are useful in many cases: for instance, where 264 we are processing samples which harbour homozygous losses or inactivating mutations in certain 265 genes (i.e., equally disruptive genomic events), or when we know in advance that certain genes are 266 controlling the same pathway, and we might speculate that a single hit in one of those decreases the 267 selection pressure on the others. We note that, with no hypothesis, a model with such alternative Phylogeny-tree reconstruction from an underlying statistical model of reads coverage or depths estimates alterations' prevalence in each clone, as well as ancestry relations. This problem is mostly worsened by the high intra-tumor heterogeneity and sequencing issues. B. The PiCnIc pipeline for ensemble-level inference includes several sequential steps to reduce tumor heterogeneity, before applying the CAPRI [40] algorithm. Available mutation, expression or methylation data are first used to stratify patients into distinct tumor molecular subtypes, usually by exploiting clustering tools. Then, subtype-specific alterations driving cancer initiation and progression are identified with statistical tools and on the basis of prior knowledge. Next is the identification of the fitness-equivalent groups of mutually exclusive alterations across the input population, again done with computational tools or biological priors. Finally, CAPRI processes a set of relevant alterations within such groups. Via bootstrap and hypothesis-testing, CAPRI extracts a set of "selective advantage relations" among them, which is eventually narrowed down via maximum likelihood estimation with regularization (with various scores). The ensemble-level progression model is obtained by combining such relations in a graph, and its confidence is assessed via various bootstrap and cross-validation techniques.
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Stratified samples (clusters)
A rank of genes and their alterations ⌘ Not all tools support all the data that is theoretically usable for a certain step.
Groups satysifying certain statistics (e.g., exclusivity)
Model Inference
Select groups of alterations which should be examined together A Boolean formula input to CAPRI tests the hypothesis that alterations in the ras genes kras, nras and braf confer equivalent selective advantage. The formula accounts for hard exclusivity of alterations in nras mutations and deletions, jointly with soft exclusivity with kras and nras alterations. Figure S3 and S4. Formulas written on groups of exclusive alterations, e.g., sox9 amplifications and mutations, are displayed in expanded form; their events are connected by dashed lines with colors representing the type of exclusivity (red for hard, orange for soft), logical connectives are squared when the formula is selected, and circular when the formula selects for a downstream node. For this model of MSS tumors in COADREAD, we find strong statistical support for many edges (p-values, bootstrap scores and cross-validation statistics shown as Supplementary Material), as well as the overall model. This model captures both current knowledge about CRC progression -e.g, selection of alterations in pi3k genes by the kras mutations (directed or via the MEMO group, with BIC) -as well as novel interesting testable hypotheses -e.g., selection of sox9 alterations by fbxw7 mutations (with BIC). In general, this model is supported by weaker statistics than MSS tumorspossibly because of this small sample size (n=27). Still, we can find interesting relations involving apc mutations which select for pik3ca ones (via BIC) as well as selection of the MEMO group (erbb2/pik3ca mutations or igf2 deletions) predicted by AIC. Similarly, we find a strong selection trend among mutations in erbb2 and kras, despite in this case the temporal precedence among those mutations is not disentangled as the two events have the same marginal frequencies (26%). B. Evolutionary trajectories of clonal expansion predicted from two selective advantage relations in the model. apc-mutated clones shall enjoy expansion, up to acquisition of further selective advantage via mutations or homozygous deletions in nras. These cases should be representative of different individuals in the population, and the ensemble-level interpretation should be that "apc mutations select for nras alterations, in hard exclusivity" as no sample harbour both alterations. A similar argument can show that the clones of patients harbouring distinct alterations in acvr1b -and different upstream events -will enjoy further selective advantage from mutation in the tgfbr2 gene.
